AbCellera (NASDAQ: ABCL) provides technologies to biotechnology and pharmaceutical partners with the goal of discovery and development of monoclonal antibody therapies. Its single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation.
Missing: AbCellera's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AbCellera's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing AbCellera
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned AbCellera in 6 CB Insights research briefs, most recently on Dec 8, 2021.
Expert Collections containing AbCellera
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AbCellera is included in 5 Expert Collections, including Digital Health.
Startups recreating how healthcare is delivered
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Digital Health 150
The winners of the second annual CB Insights Digital Health 150.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AbCellera has filed 1 patent.
Immunology, Animal virology, Epidemiology, Animal viral diseases, Clusters of differentiation
Immunology, Animal virology, Epidemiology, Animal viral diseases, Clusters of differentiation
Latest AbCellera News
Nov 16, 2022
mbbirdy Truist has initiated AbCellera Biologics (NASDAQ: ABCL ) with a buy citing the company's platform that allows for the rapid discovery of antibodies. The firm has a price target of $29 per share (100% upside based on Tuesday's close). Analyst Robyn Karnauskas said that the platform is validated by the approval of two COVID drugs and five candidates in the clinical stage. In addition, its "partnership-based business model has led to consistent revenues, atypical in a young biotech." She added that she believes the company is undervalued and sees potential upside over the next year to two due to additional partnerships, further validation of the platform, and validation from other companies in the space. Read why Seeking Alpha contributor Confoundedinterest rates AbCellera ( ABCL ) a strong buy. Recommended For You
AbCellera Web Traffic
AbCellera Frequently Asked Questions (FAQ)
When was AbCellera founded?
AbCellera was founded in 2012.
Where is AbCellera's headquarters?
AbCellera's headquarters is located at 2215 Yukon Street, Vancouver.
What is AbCellera's latest funding round?
AbCellera's latest funding round is IPO.
How much did AbCellera raise?
AbCellera raised a total of $247.07M.
Who are the investors of AbCellera?
Investors of AbCellera include DCVC, Viking Global Investors, Peter Thiel, OrbiMed Advisors, Founders Fund and 11 more.
Who are AbCellera's competitors?
Competitors of AbCellera include Abveris and 4 more.
Compare AbCellera to Competitors
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics
Cervelo Pharmaceuticals is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate, which has demonstrated a safe and potentially effective capability against neuropathic and inflammatory pain, as well as inflammation.
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
Plymouth Marine Laboratory (PML) has been conducting research into marine organisms for more than 20 years funded by NERC. EcoAlert Ltd has been formed by PML's wholly owned technology transfer company, Plymouth Marine Applications Ltd (PMA), to commercialise a bioassay technique arising from this work. The Company has exclusive rights to ECOBOX, a portable bioassay kits for in-situ analysis of marine, estuarine and freshwater aquatic environments.
Nobody prototypes a jet plane or car without running the empirical data through a computer model. A clinical trial is also a prototype. Now, pharmaceutical companies can simulate as many scenarios as necessary to optimize success in the final design of their clinical trials.nBiosimulation technology from Immunetrics Inc. aims to provide a bridge from research and experiment to trial design. Immunetrics' toolset aims to provide predictive computer models based on biological mechanisms. The inputs are patient data; the outputs are predictions of clinical markers over time and clinically relevant endpoints. Using this data, Immunetrics creates a simulation platform for conducting virtual experiments that can help pharmaceutical companies lock down the design of a human study that is optimized for success.nImmunetrics is the only known mechanistic modeling company to provide predictions of clinical trial outcomes that go far beyond pass or fail.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.